Celebrating 20 years of innovation - Discover how we've been a catalyst for regional growth and UK innovation for over two decades in CPI's Annual Review 2023-2024.

Welcome to the future of innovation in oligonucleotide manufacturing

We are delighted to announce the launch of our new, state-of-the-art oligonucleotide pharmaceutical manufacturing facility, now serving the United States pharmaceutical market.


To be the first to find out when we are fully open to industry, please complete this form.

pharamceutical vials

A game-changer in pharmaceutical manufacturing

Based in Scotland, UK, our facility is designed to meet the growing demand for oligonucleotide-based therapies. Equipped with the latest advancements in manufacturing technologies, our facility ensures high-yield, scalable, and cost-efficient production while adhering to the highest standards of safety and compliance.

With GMP certification expected in 2025, we will be able to manufacture clinical trial material.

vector image

Why this facility matters

  • Advanced technology: Leveraging innovative processes and automation to deliver consistent, high-quality products.
  • Scalability: Capable of supporting projects from early-stage development through to clinical trials and beyond.
  • Quality assurance: Built to ensure the highest level of GMP-manufacturing compliance and product integrity.
  • Targeted: Positioned to serve US pharmaceutical innovators with faster delivery times and reduced logistical complexities, by providing the right quality in the right quantity at the right time.

To talk to us directly about this new facility, please email Andrew White.

CPI is your innovation partner to make your ideas a reality.